Annual report pursuant to Section 13 and 15(d)

Note 3 - Summary of Significant Accounting Policies: Research and Development (Policies)

v3.8.0.1
Note 3 - Summary of Significant Accounting Policies: Research and Development (Policies)
12 Months Ended
Dec. 31, 2017
Policies  
Research and Development

Research and Development

 

Research and development costs are expensed as incurred. The majority of the Company's research and development costs consist of clinical study expenses. These consist of fees, charges, and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. External clinical studies expenses were $2,381,222 and $788,971 for the years ended December 31, 2017 and 2016, respectively.